Enveric Biosciences Inc (ENVB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,241 | 3,112 | 3,503 | 6,356 | 2,288 |
| TOTAL | $2,735 | $4,338 | $5,520 | $8,229 | $3,582 |
| Non-Current Assets | |||||
| PPE Net | 306 | 368 | 405 | 452 | 507 |
| Intangibles | 42 | 84 | 127 | 169 | 211 |
| TOTAL | $348 | $452 | $532 | $621 | $718 |
| Total Assets | $3,083 | $4,790 | $6,052 | $8,850 | $4,300 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 755 | 576 | 460 | 1,853 | 1,219 |
| Other current liabilities | N/A | 10 | 9 | 28 | 49 |
| TOTAL | $1,490 | $839 | $645 | $2,368 | $2,344 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,490 | $839 | $645 | $2,368 | $2,344 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 206 | 55 | 50 | 43 | 41 |
| Common Shares | 1 | 90 | 79 | 73 | 2 |
| Retained earnings | -106,075 | -102,920 | -100,836 | -98,956 | -96,500 |
| Other shareholders' equity | -595 | -535 | -567 | -552 | -2,387 |
| TOTAL | $1,593 | $3,951 | $5,406 | $6,482 | $1,956 |
| Total Liabilities And Equity | $3,083 | $4,790 | $6,052 | $8,850 | $4,300 |